Tessera private stock trade

Tessera

Legal NameTessera Therapeutics, Inc.
HeadquartersCambridge, MA
SectorBioTech

Tessera Therapeutics is a biotechnology company pioneering Gene Writing™, a groundbreaking technology that enables precise and efficient genetic modifications for therapeutic purposes. The company specializes in developing innovative treatments for a wide range of diseases by harnessing the power of gene editing and synthetic biology. Tessera Therapeutics focuses on advancing gene therapies that can address complex genetic disorders with high precision and safety. Its research and development efforts integrate cutting-edge technologies to engineer therapeutic genetic circuits and optimize delivery methods, aiming to transform the landscape of genetic medicine. The company is committed to advancing healthcare through its innovative approach to genetic engineering and therapeutic development.

Learn more about Tessera IPO

Secondary Pricing Information

$ .star in blue circleZX Index Value | Get ZXData access
--ZX Index Value VS Reported Marks
pricing graph placeholder
star in blue circleTo view Pre-IPO pricing data for Tessera, log in to ZXData or contact us to request access.
<

Secondary Volume Information

$ .M star in blue circleAggregate Volume | Get ZXData access
volume graph placeholder
star in blue circleTo view Pre-IPO volume data for Tessera, log in to ZXData or contact us to request access.
View More

ZXData is a leading provider of real-time secondary data on private companies. ZXData's dataset incoroporates closed trades with 20bn+ in volume. In addition, it incorporates $200bn+ of buy/sell prices and $56bn+ of reported marks to provide private market investors, trading desks, lenders, and companies with unprecedented market intelligence on private companies.

Disclaimer

This report is provided for informational purposes only and does not constitute a recommendation or solicitation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. The values shown in this report are not indicative price quotations. This report does not constitute investment advice, nor does this report constitute a "research report" as defined by FINRA Rule 2241 or a "debt research report" as defined by FINRA Rule 2242.

The ZXData and the information contained in this report, some of which have been obtained from third-party sources, are provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. Neither Zanbato Inc. (“Zanbato”) nor its affiliates guarantee the accuracy or completeness of the data contained in this report, or its computation and compilation.

The ZXData and this report constitute Zanbato’s valuable intellectual property. You are expressly prohibited from copying, modifying, transmitting or redistributing the ZXData or this report without Zanbato’s prior written consent.